<DOC>
	<DOCNO>NCT00499018</DOCNO>
	<brief_summary>The purpose study define improvement patient randomize four different arm : Arm 1 : R-MegaCHOP14x4 + R-MAD + MAD + BEAM + ASCT ; Arm 1BIS : R-CHOP14x4 + R-MAD + MAD + BEAM + ASCT ; Arm 2 : R-MegaCHOP14x4 + R-MegaCHOP14x2 ; Arm 2BIS : R-CHOP14x4 + R-CHOP14x4 ; Which different dose dense chemotherapy + Rituximab without intensified high dose chemoimmunotherapy support peripheral autologous stem cell .</brief_summary>
	<brief_title>Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support Peripheral Autologous Stem Cell Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Age 1860 ; 2 . Histological confirm diagnosis Diffuse Large BCell Lymphoma CD20+ ( newly diagnosis shift low grade NHL previously treat ) Follicular Lymphoma grade III accord REAL/WHO Classification . 3 . Advanced stage II , stage III stage IV least two aaIPI risk factor . 4 . Ageadjusted IPI 23 . 5 . ECOG performance status 02 . 6 . LVEF &gt; 45 % , measure echocardiography . 7 . Normal hepatic , renal pulmonary function . 8 . HIV , HCV HBV negativity . 9 . HCV+ admit histologically confirm absence replication mark . 10 . Positive serology HBV ( occult carrier : AntiHBcAg+ , HbsAg , AntiHBsAg+/ ) admit upon negativity weakly positive HBVDNA test . 11 . Life expectancy &gt; 3 month . 12 . Negative pregnancy test . 13 . Written Informed Consent . 1 . Histological diagnosis : Lymphoblastic NHL Burkitt 's Lymphoma CD 20 negative Bcell Lymphoma grade IIIIa Follicular Lymphoma Mantle Cell Lymphoma Primary mediastinal NHL exclusively intrathoracic localization . 2 . Age &gt; 60 3 . Stage I disease 4 . Ageadjusted IPI 01 5 . ECOGPS &gt; 3 , relate Lymphoma 6 . Renal impairment ( creatinine &gt; 1,2 mg/dl creatinine clearance &lt; 60ml/min ) 7 . Hepatic impairment ( AST/ALT bilirubin &gt; 2,5 time normal limit , unless due Lymphoma ) 8 . HIV positive patient and/or HBV HCV active infection ( document HBVDNA HCVRNA positive test ) 9 . Clinically significant secondary cardiovascular disease e.g . uncontrolled hypertension ( rest diastolic blood pressure &gt; 115 mmHG ) , uncontrolled multifocal cardiac arrhythmia , symptomatic angina pectoris congestive cardiac failure NYHA class IIIIV 10 . LFEV &lt; 45 % 11 . Severe diabetes mellitus difficult control adequate insulin therapy 12 . Severe chronic obstructive pulmonary disease hypoxemia 13 . Active bacterial , viral fungal infection require systemic therapy 14 . Concurrent thrombohemolytic disease 15 . HIV positivity 16 . HBV positivity 17 . Positive serology HBV ( occult carrier : AntiHBc+ , HbsAg , AntiHbs+/ ) positive HBVDNA test 18 . HCV positivity presence replication mark ( HCV+ , CRP+ , AST 1,52 time normal range ) 19 . CNS localization disease 20 . Prior ( last 3 year ) concurrent malignancy except adequately treat basal cell carcinoma skin carcinoma situ cervix early stage prostate cancer require systemic therapy , early breast cancer treat surgery alone . Any co.existing medical condition would preclude study therapy administration 21 . Pregnancy breastfeed woman 22 . Inability patient give her/his inform consent 23 . Known hypersensitivity anaphylactic reaction murine antibody protein</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Large B-Cell Lymphoma</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Autologous Stem Cell Transplantation</keyword>
</DOC>